Cancer Prevention II

1. Front Matter

   Pages i-xx

   PDF

2. Cancer Prevention and Health Politics

   1. Do We Make Optimal Use of the Potential of Cancer Prevention?

      • Peter Greenwald, Barbara K. Dunn

      Pages 3-17

   2. Predictors of Successful Cancer Prevention Programs

      • Franz Porzsolt, Anita Kirner, Robert M. Kaplan

      Pages 19-31

   3. Cancer Prevenpinon in the Developing World: Mission Impossible?

      • Franco Cavalli

      Pages 33-39

   4. Is Cancer Prevention Ever Going to Be Profitable?

      • Thomas D. Szucs, Konstantin J. Dedes

      Pages 41-47

3. Cancer Prevention: The Scientific-Epidemiological Base

   1. Energy Metabolism, Cancer Risk, and Cancer Prevention

      • Michael Pollak

      Pages 51-54

   2. Promises and Limitations of Biomarkers

      • David F. Ransohoff

      Pages 55-59

4. Cancer Prevention, Tobacco and Nutrition

   1. The EPIC Study: An Update

      • Paolo Vineis, Elio Riboli

      Pages 63-70

   2. Anti-angiogenic properties of Chemopreventive Drugs: Fenretinide as a Prototype.

      • Ilaria Sogno, Roberta Venè, Cristina Sapienza, Nicoletta Ferrari, Francesca Tosetti, Adriana Albini

      Pages 71-76

   3. Retinoids and Breast Cancer Prevention

      • Bernardo Bonanni, Matteo Lazzeroni

      Pages 77-81

5. Cancer Prevention, Genetics and Vaccines

   1. Cancer Prevention by Vaccination Against Hepatitis B

      • Mei-Hwei Chang

      Pages 85-94

6. Cancer Prevention and Target Organs I: Breast Cancer

   1. Energy Restriction for Breast Cancer Prevention

      • Anthony Howell, Mary Chapman, Michelle Harvie

      Pages 97-111

   2. The Use of Tamoxifen and Raloxifene for the Prevention of Breast Cancer

      • D. Lawrence Wickerham, Joseph P. Costantino, Victor G. Vogel, Walter M. Cronin, Reena S. Cecchini, Leslie G. Ford et al.

      Pages 113-119

   3. Prevention of ER-Negative Breast Cancer

      • Yuxin Li, Powel H. Brown

      Pages 121-134

   4. EHxoorgmeonnoeuss, aMnadmEmndooggraepnhoiucs Density and Breast Cancer Risk: Can Mammographic Density Be Considered an Intermediate Marker of Risk?

      • Susen Becker, Rudolf Kaaks

      Pages 135-157

7. Cancer Prevention and Target Organs II: Cancer of the Digestive Tract

   1. Chemoprevention of Oesophageal Cancer and the AspECT Trial

      • Debasish Das, Andrew P. Chilton, Janusz A. Jankowski

      Pages 161-169

8. Cancer Prevention and Target Organs III: Prostate Cancer

   1. Review of Diagnostic Markers for Prostate Cancer 16

      • Fritz H. Schröder

      Pages 173-182

   2. Seleneium and Vitamin E Cancer Prevention Trial: A Nutrient Approach to Prostate Cancer Prevention

      • Barbara K. Dunn, Anne Ryan, Leslie G. Ford

      Pages 183-193

   3. Prostate Cancer Prevention by Short-Term Anti-androgens: The Rationale Behind Design of Pilot Studies

      • Tim Oliver, Attila Lorincz, Jack Cuzick

      Pages 195-205

9. Cancer Prevention and Target Organs III: Prostate Cancer

   1. Anti-angiogenic Activity of a Novel Class of Chemopreventive Compounds: Oleanic Acid Terpenoids

      • Ilaria Sogno, Nicola Vannini, Girieca Lorusso, Rosaria Cammarota, Douglas M. Noonan, Luca Generoso et al.

      Pages 209-212

More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on “Primary Therapy of Early Breast Cancer” as well as “Supportive Care in Cancer” for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since today’s medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In Switzerland—and we fear in many other parts of the globe—some 97%–98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2%–3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for “curing and caring” for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population.

• ER-negative breast cancer
• Prevention of breast cancer
• Primary prevention
• cancer prevention
• chemoprevention
• prevention

• Zentrum fücr Tumordiagnostik und Prävention, St. Gallen, Schweiz

  Hans-Jörg Senn, Ursula Kapp, Florian Otto

Policies and ethics